Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Chemocentryx Inc patents


Recent patent applications related to Chemocentryx Inc. Chemocentryx Inc is listed as an Agent/Assignee. Note: Chemocentryx Inc may have other listings under different names/spellings. We're not affiliated with Chemocentryx Inc, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "C" | Chemocentryx Inc-related inventors


Azaindazole compounds and methods of use

Compounds are provided that act as potent antagonists of the ccr1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of ccr1-mediated diseases, and as controls in assays for the identification of competitive ccr1 antagonists.. ... Chemocentryx Inc

C5ar antagonists

Compounds are provided that are modulators of the c5a receptor. The compounds are substituted piperidines and are useful in pharmaceutical compositions, methods for the treatment of diseases and disorders involving the pathologic activation of c5a receptors.. ... Chemocentryx Inc

Inhibitors of cxcr2

Compounds are provided as inhibitors of cxcr2, having the structure:. . ... Chemocentryx Inc

Substituted anilines as ccr(4) antagonists

Aniline compounds are provided which bind to ccr(4) and are useful for the treatment of diseases such as allergic diseases, autoimmune diseases, graft rejection and cancer.. . ... Chemocentryx Inc

Modulators of chemokine receptors

Compounds are provided as chemokine inhibitors having the structure:. . ... Chemocentryx Inc

Method of treating focal segmental glomerulosclerosis

A method of treating focal segmental glomerulosclerosis with a compound of formula i is provided. Fsgs may be primary (no known cause) or secondary. ... Chemocentryx Inc

Substituted benzimidazoles and benzopyrazoles as ccr(4) antagonists

Benzimidazole, benzopyrazole and benzotriazole compounds are provided which bind to ccr(4) and are useful for the treatment of diseases such as allergic diseases, autoimmune diseases, graft rejection and cancer.. . ... Chemocentryx Inc

Ccr6 compounds

Compounds of formula (i) are provided which are useful in the treatment of diseases or conditions modulated at least in part by ccr6:. . ... Chemocentryx Inc

Processes and intermediates in the preparation of c5ar antagonists

. . . . Intermediates and methods are provided for the preparation of selected c5ar antagonist compounds.. . ... Chemocentryx Inc

Diazole amides

Compounds are provided that act as potent antagonists of the ccr1 receptor, and have in vivo anti-inflammatory activity. The compounds are diazole lactam derivatives and are useful in pharmaceutical compositions, methods for the treatment of ccr1-mediated disease, and as controls in assays for the identification of competitive ccr1 antagonists.. ... Chemocentryx Inc

Polymorphic forms of the sodium salt of 4-tert- butyl -n-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzene sulfonamide

Disclosed are novel polymorphic solvated and desolvated forms of the sodium salt of 4-tert-butyl-n-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzenesulfonamide and pharmaceutical compositions containing the same. Also disclosed are processes for the preparation thereof and methods for use thereof.. ... Chemocentryx Inc

Aza-aryl 1h-pyrazol-1-yl benzene sulfonamides

. . Compounds are provided that act as potent antagonists of the ccr(9) receptor for treating sjogren's syndrome. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions.. ... Chemocentryx Inc

Aryl sulfonamides

Compounds are provided that act as potent antagonists of the ccr9 receptor, and which have been further confirmed in animal testing for inflammation, one of the hallmark disease states for ccr9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of ccr9-mediated diseases, and as controls in assays for the identification of ccr9 antagonists.. ... Chemocentryx Inc

Method of treating pancreatic cancer

The present disclosure describes methods of treating pancreatic cancer and limiting over-expression of oncogenes, activating tumor suppressor genes or regulating signaling proteins in patients comprising administering compounds and pharmaceutical combinations as described herein.. . ... Chemocentryx Inc

12/14/17 / #20170354657

Method of treating pancreatic cancer

The present disclosure describes methods of treating pancreatic cancer and limiting over-expression of oncogenes, activating tumor suppressor genes or regulating signaling proteins in patients comprising administering compounds and pharmaceutical combinations as described herein.. . ... Chemocentryx Inc

12/07/17 / #20170348293

Method of treating liver fibrosis

A method of treating liver fibrosis with ccr2 antagonists is provided. The liver fibrosis may be associated with non-alcoholic steatohepatitis (nash), non-alcoholic fatty liver disease (nafld), emerging cirrhosis, non-cirrhotic hepatic fibrosis, type 2 diabetes mellitus (t2dm) or metabolic syndrome (ms).. ... Chemocentryx Inc

11/23/17 / #20170334920

Fused heteroaryl pyridyl and phenyl benzenesuflonamides as ccr2 modulators for the treatment of inflammation

Compounds are provided that act as potent antagonists of the ccr2 receptor. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of ccr2-mediated diseases and as controls in assays for the identification of ccr2 antagonists.. ... Chemocentryx Inc

11/16/17 / #20170327508

Deuterated heteroaryl sulfonamides and their use

Compunds are provided that act as potent antagonists of the ccr2 receptor. These compounds are useful for treating inflammation, a hallmark disease for ccr2. ... Chemocentryx Inc

10/12/17 / #20170290808

Reducing tumor burden by administering ccr1 antagonists in combination with pd-1 inhibitors or pd-l1 inhibitors

The present invention provides methods for reducing tumor burden, tumor growth, tumor progression, and/or metastasis in a subject suffering from a solid tumor cancer such as triple negative breast cancer. The methods include administering to a subject in need thereof a therapeutically effective amount of a pd-l1 inhibitor or a pd-1 inhibitor in combination with a small molecule chemokine receptor antagonist that blocks ccr1.. ... Chemocentryx Inc

07/20/17 / #20170204087

2-oxindole compounds

. . Oxindole compounds useful for the treatment of ccr(9) mediated conditions or diseases are provided.. . ... Chemocentryx Inc

07/20/17 / #20170202821

Method of treating c3 glomerulopathy

Methods of treating a human suffering from or susceptible to c3 glomerulopathy comprising administering to the human an effective amount of a c5ar antagonist are provided.. . ... Chemocentryx Inc

04/27/17 / #20170114017

C5ar antagonists

Compounds are provided that are modulators of the c5a receptor. The compounds are substituted piperidines and are useful in pharmaceutical compositions, methods for the treatment of diseases and disorders involving the pathologic activation of c5a receptors.. ... Chemocentryx Inc

04/06/17 / #20170095458

Heteroaryl sulfonamides and ccr2/ccr9

Compounds are provided that act as potent antagonists of the ccr2 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for ccr2. ... Chemocentryx Inc

03/09/17 / #20170065604

C5ar antagonists

Compounds are provided that are modulators of the c5a receptor. The compounds are substituted piperidines and are useful in pharmaceutical compositions, methods for the treatment of diseases and disorders involving the pathologic activtation of c5a receptors.. ... Chemocentryx Inc

01/26/17 / #20170022205

Fused heteroaryl pyridyl and phenyl benzenesuflonamides as ccr2 modulators for the treatment of inflammation

Compounds are provided that act as potent antagonists of the ccr2 receptor. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of ccr2-mediated diseases and as controls in assays for the identification of ccr2 antagonists.. ... Chemocentryx Inc

01/26/17 / #20170022161

Polymorphic forms of the sodium salt of 4-tert- butyl -n-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzene sulfonamide

Disclosed are novel polymorphic solvated and desolvated forms of the sodium salt of 4-tert-butyl-n-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)phenyl]-benzenesulfonamide. One embodiment of the present invention is directed to a crystalline sodium salt of 4-tert-butyl-n-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]benzenesulfonamide (hereinafter “compound a-1,4-di-oxane/water solvate”), wherein the crystalline form is characterized by an x-ray powder diffraction pattern comprising diffraction angles (°28), when measured using cu ku radiation, at about 4.0, 8.1, 10.1, 14.2, 16.2, 18 6, 20.3, 24.7, 25.0, and 26.5.. ... Chemocentryx Inc








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Chemocentryx Inc in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Chemocentryx Inc with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###